0.0002  0 (0%)		04-24 15:47
Open: 0.0002 High: 0.0002 Volume: 5,076		Pre. Close: 0.0002 Low: 0.0002 Market Cap: 0(M)

Short term
Mid term
Targets	6-month :		1-year :
Resists	First :		Second :
Pivot price
Supports	First :		Second :
MAs	MA(5) :		MA(20) :
	MA(100) :		MA(250) :
MACD	MACD :		Signal :
%K %D	K(14,3) :		D(3) :
RSI	RSI(14):
52-week	High :		Low :

If tomorrow:	Open lower	Open higher
High:	-	-
Low:	-	-
Close:	-	-

Echo Therapeutics, Inc. specializes in creating transdermal skin permeation and diagnostic medical devices. Their offerings primarily target the wearable health consumer market and individuals with diabetes requiring outpatient care. The company is currently advancing a cutting-edge, needle-free, wireless Continuous Glucose Monitoring (CGM) system, specifically tailored for hospital settings across the European Union. Echo Therapeutics maintains several strategic alliances. They hold a licensing partnership with Ferndale Pharma Group, Inc., encompassing the development, manufacturing, distribution, and commercialization of devices used for skin preparation. These devices are applied before topical anesthetics or analgesics are administered, particularly preceding a variety of needle-based medical procedures. The geographical scope of this collaboration includes North America, the United Kingdom, South America, Australia, New Zealand, Switzerland, and other regions within the European Union. Furthermore, the company has secured a licensing arrangement with Handok Pharmaceuticals Co., Ltd. This partnership covers the development, utilization, marketing, importation, and sale of its CGM technology to both healthcare institutions and private individuals in South Korea. A separate license, development, and commercialization agreement is also in effect with Medical Technologies Innovation Asia, Ltd., focusing on the research, development, production, and deployment of CGM systems throughout the People's Republic of China, Hong Kong, Macau, and Taiwan. Established in 1989, Echo Therapeutics, Inc. maintains its principal office in Iselin, New Jersey.

Mon, 28 Nov 2022
Patrick T Mooney Net Worth (2026) - GuruFocus

Sun, 27 Nov 2022
Mark Nordlicht Net Worth (2026) - GuruFocus

Tue, 14 Nov 2017
Echo Therapeutics (ECTE) Stock Price, News & Analysis $ECTE - MarketBeat

Tue, 09 Jun 2026

Tue, 09 Jun 2026

Tue, 09 Jun 2026

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: OTC
Sector: Healthcare
Industry: Medical - Devices
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	(%)
Held by Institutions	(%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS
EPS Est Next Qtrly
EPS Est This Year
EPS Est Next Year
Book Value (p.s.)
Profit Margin	%
Operating Margin	%
Return on Assets (ttm)	%
Return on Equity (ttm)	%
Qtrly Rev. Growth	%
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth	%
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio
PEG Ratio
Price to Book value
Price to Sales
Price to Cash Flow

Dividend
Forward Dividend
Dividend Yield	0%
Dividend Pay Date
Ex-Dividend Date